Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

被引:19
|
作者
Kamrava, Mitchell [1 ,2 ]
Chung, Melody P. [1 ]
Kayode, Oluwatosin [1 ]
Wang, Jason [1 ]
Marks, Leonard [3 ]
Kupelian, Patrick [1 ]
Steinberg, Michael [1 ,2 ]
Park, Sang-June [1 ]
Demanes, D. Jeffrey [1 ,2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA
[2] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
关键词
Prostate; Focal therapy; Brachytherapy; LOCALIZED PROSTATE-CANCER; PHASE-II TRIAL; HDR BRACHYTHERAPY; RADICAL PROSTATECTOMY; RADIATION-THERAPY; FREE SURVIVAL; FOLLOW-UP; MONOTHERAPY; TOXICITY; CRYOABLATION;
D O I
10.1016/j.brachy.2012.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: To determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment. METHODS AND MATERIALS: A total of 10 WG implants were used to generate 10 WG and 20 HG (left and right) treatment plans optimized with the inverse planning simulation annealing algorithm using Oncentra MasterPlan (Nucletron B.V., Veenendaal, The Netherlands). The standard distribution of 17-18 catheters designed for WG was used to generate HG plans. The same OARs namely bladder, rectum, and urethra contours and dose constraints were applied for HG and WG plans. The HG contour was a modification of the WG contour whereby the urethra divided the prostate into HGs. The prescription dose was 7.25 Gy x 6. Evaluated dose parameters were target dose D-90, V-100, and V-150 and D-0.1 (cc) D-1 and D-2 (cc) to OARs. RESULTS: The HG plans had a D-90, V-100, and V-150 to the HG target of 112%, 97.6%, and 33.8%, respectively. The WG plans had a D-90, V-100, and V-150 to the WG target of 108%, 98.8%, and 26.5%, respectively. The OAR D-2 (cc) doses were significantly lower in HG vs. WG plans: rectum (53.1% vs. 64.1%, p<0.0001), bladder (55.9% vs. 67.5%, p<0.0001), and urethra (69.3% vs. 95.2%, p<0.0001). CONCLUSIONS: In the present model, HG plans yielded a statistically significant decreased radiation dose to OARs and provided complete target coverage with a catheter array designed for WG coverage. The good dosimetry results obtained in this study support the feasibility of HG brachytherapy by using a subset of the WG catheter array. Catheter distribution and dosimetry refinements tailored to subtotal prostate brachytherapy should be explored to see if further improvements in dosimetry can be achieved. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:434 / 441
页数:8
相关论文
共 50 条
  • [31] High-dose-rate brachytherapy with external beam radiotherapy in the treatment of carcinoma of cervix: dosimetric and radiobiologic analysis
    Passi, Kamlesh
    Kehwar, Than S.
    Vashistha, Rajesh
    Singh, Bikramjit
    Jain, Veena
    Gupta, Sureshchandra J.
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2009, 8 (04) : 215 - 227
  • [32] A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy
    Mesko, Shane
    Park, Sang-June
    Kishan, Amar U.
    Demanes, D. Jeffrey
    Kamrava, Mitchell
    BRACHYTHERAPY, 2015, 14 (02) : 173 - 178
  • [33] Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer
    Hosni, Ali
    Carlone, Marco
    Rink, Alexandra
    Menard, Cynthia
    Chung, Peter
    Berlin, Alejandro
    RADIOTHERAPY AND ONCOLOGY, 2017, 122 (01) : 103 - 108
  • [34] A dose verification method for high-dose-rate brachytherapy treatment plans
    Kumar, Rajesh
    Sharma, S. D.
    Vijaykumar, C.
    Deshpande, Sudesh
    Sharma, P. K.
    Vandana, S.
    Philomena, A.
    Chilkulwar, Ravi H.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2008, 4 (04) : 173 - 177
  • [35] Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: 192Ir, 60Co and an electronic brachytherapy source
    Mobit, Paul N.
    Nguyen, Alex
    Packianathan, Satyaseelan
    He, Rui
    Yang, Claus C.
    BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1059):
  • [36] A dosimetric study of electron beam therapy vs. high-dose-rate mould brachytherapy in adjuvant treatment of non-melanoma skin carcinomas of the head and neck region
    Sen, Souransu
    Bandyopadhyay, Anis
    Pal, Jayanta Kumar
    Ghosh, Arnab Kumar
    Deb, Asit Ranjan
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (06) : 547 - 553
  • [37] High-dose-rate interstitial brachytherapy vs external beam radiation for the treatment of complex keloids
    Liao, Yixiang
    Dorafshar, Amir H.
    Bernard, Damian
    Kim, Thomas
    Camden, Nathaniel B.
    Wang, Dian
    MEDICAL DOSIMETRY, 2022, 47 (02) : 158 - 160
  • [38] High-dose-rate brachytherapy for the treatment of nonmelanoma skin cancer
    Huang, Ya-Yun
    Lan, Cheng-Che
    Tang, Jen-Yang
    DERMATOLOGICA SINICA, 2019, 37 (04) : 233 - 234
  • [39] Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes
    Laing, Robert
    Franklin, Adrian
    Uribe, Jennifer
    Horton, Alex
    Uribe-Lewis, Santiago
    Langley, Stephen
    RADIOTHERAPY AND ONCOLOGY, 2016, 121 (02) : 310 - 315
  • [40] High-dose-rate brachytherapy for high-grade vaginal intraepithelial neoplasia: a dosimetric analysis
    Barcellini, Amelia
    Lecchi, Mara
    Tenconi, Chiara
    Macciotta, Alessandra
    Pignoli, Emanuele
    Pappalardi, Brigid
    Mozzarella, Ester
    Carrara, Mauro
    Giandini, Tommaso
    Fallai, Carlo
    Verderio, Paolo
    Cerrotta, Annamaria
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (02) : 146 - 151